Putting patient wellbeing and collaboration at the heart of what we do

Which treatment or diagnostic would make a patient’s life better? This is the starting point of what…

Rethinking drug research, before it’s too late

As we face the prospect of living in a ‘post-antibiotic’ era, there is renewed urgency to rethink…

MRC Technology, UCB and the University of Leicester combine research excellence and expertise to evolve drug discovery

New research consortium aims to identify opportunities for drug discovery through the innovative use of antibodies in structure-based drug discovery and design.

New collaboration to explore novel treatments for respiratory diseases

A charity-industry collaboration has launched an initiative to find new epigenetic drug treatments to improve the lives of millions of people affected by respiratory diseases every year.

MRC Technology monetises royalties on cancer drug Keytruda® (pembrolizumab) to expand medical research activities, with a fund managed by DRI Capital

MRC Technology has monetised a portion of its royalty interest in a leading cancer drug, pembrolizumab (marketed by Merck & Co., Inc. as Keytruda®) with a private equity fund managed by DRI Capital (DRI) for US $150M (£115.6M).

MRC Technology and Keio University to collaborate on drug discovery

MRC Technology and Keio University School will collaborate to identify promising antibody and small molecule research and translate them into early stage assets.

Patent protection for biotech/genetic engineering: report

Andrew Farquarson, Director, Technology Transfer, has been a member of the EU Commission’s Expert Group appointed in 2012…

Enhancing patient benefit from research spending: MRC Technology and DEBRA Austria sign agreement

MRC Technology, a medical research charity, has signed an agreement to review DEBRA Austria’s research portfolio, aiming to identify promising projects and results which could be suitable for translation into better treatments.

Keytruda receives another breakthrough designation

(Antibody humanised by MRC Technology) Merck, known as MSD outside the United States and Canada, announced that…